ClinicalTrials.gg
RecruitingNCT07043946Updated Mar 27, 2026

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

A Phase 1/2 interventional study of Budoprutug in Immune Thrombocytopenia (ITP), ITP and Biologics, sponsored by Climb Bio, Inc.. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Climb Bio, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine — 1 open to participants now, 1 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Ukraine.

Planned enrollment
16th of 16
24 · median 54
Started
2025
the only one that year
Phase 1/2
Only one
of the 16
Registered
16th of 16
by date
Lead sponsor
1 of 16
Climb Bio, Inc.

Among the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, this one is the 16th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 16th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

1 of the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine is open now.

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, or all of them as a file.
02

Study summary

The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Read the detailed description

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label, sequential-cohort, dose escalation and expansion study will evaluate the safety, tolerability, PK, PD, and preliminary clinical effectiveness of budoprutug in subjects with ITP. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts of patients aged 18 years and above with a platelet count \< 30,000/µL despite an adequate trial of at least one prior therapeutic attempt.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)
  • ITP
  • Biologics
  • Monoclonal
  • Anti-CD19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years at the time of consent.
  2. count \< 30,000/µL despite an adequate trial of at least one prior therapeutic attempt. Platelet counts of \< 30,000/µL must be confirmed on 2 occasions at least 5 days apart, but no more than 14 days apart.
  3. \< 1.5 x (ULN), prothrombin time \< 1.5 x ULN, total \< 1.5 x ULN unless due to Gilbert's syndrome, or an international normalized ratio \< 1.5 at screening.

Exclusion criteria

Exclusion Criteria:

  1. CD19+ B cell count \< 80 cells/µL at Screening, or \< 40 cells/µL if B-cell depleting therapy was received within 24 weeks to 2 years prior.
  2. Diagnosis of paroxysmal nocturnal hemoglobinuria, Evan's Syndrome, or other bleeding disorders affecting safety or data integrity.
  3. Prior B-cell depleting therapy (e.g., rituximab) within 24 weeks before first dose or planned during the study.
  4. Chronic use of anticoagulants or antiplatelet agents (e.g., aspirin, NSAIDs, thienopyridines) within 14 days before dosing through follow-up. Intermittent NSAID use is allowed.
  5. (excluding ) within 30 days or 5× half-life before Screening; alkylating agents within 180 days.
  6. IVIg treatment within 90 days prior to Screening.
  7. Active ITP treatment (other than steroids or TPO agonists) within 30 days or 5× half-life before first dose, unless approved by Medical Monitor.
  8. Active, chronic, or latent infections including /C or .
  9. Active TB or high TB risk.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level A

    Single IV dose of study product on Day 1 and on Day 15

    Drug: Budoprutug

  • Experimental
    Cohort 2: Dose Level B

    Single IV dose of study product on Day 1 and on Day 15

    Drug: Budoprutug

  • Experimental
    Cohort 3: Dose Level C

    Single IV dose of study product on Day 1 and on Day 15

    Drug: Budoprutug

  • Experimental
    Dose Expansion Cohort

    Single IV dose of study product on Day 1 and Day 15

    Drug: Budoprutug

Interventions

  • Single IV dose of study product on Day 1 and Day 15

    Also known as: TNT119

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.

    Time frame: Up to week 48

Secondary outcomes

  1. Area Under the Curve (AUC)

    Measurement of the area under the drug concentration-time curve.

    Time frame: Up to week 48

  2. Maximum Observed Plasma Concentration (Cmax)

    Measurement of the maximum observed plasma concentration.

    Time frame: Up to week 48

  3. Time to Maximum Observed Concentration (Tmax)

    Measurement of the time to maximum observed concentration.

    Time frame: Up to week 48

  4. Terminal Half-Life (T1/2)

    Measurement of the terminal half-life in days.

    Time frame: Up to week 48

  5. Apparent Clearance (CL/F)

    Measurement of the apparent clearance in L/hour.

    Time frame: Up to week 48

  6. Change from Baseline in CD20+ B-cell Count

    Change in absolute peripheral CD20+ B-cell count

    Time frame: Up to week 48

  7. Change in Platelet Count

    Change in platelet count over time

    Time frame: Up to week 48

  8. Proportion of Participants with stable, partial or complete platelet response

    Percentage of participants with stable, partial or complete platelet response.

    Time frame: Up to week 48

  9. Incidence of Anti-Drug Antibodies (ADAs)

    Number of participants with detectable ADAs.

    Time frame: Up to week 48

  10. Steroid Discontinuation Rate

    % of baseline steroid users who discontinue steroids.

    Time frame: Up to week 48

07

Study locations

18 of 20 sites recruiting
  • Climb Bio Investigative Site #359202
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Climb Bio Investigative Site #359203
    Plovdiv, 4003, Bulgaria
    Recruiting
  • Climb Bio Investigative Site #359201
    Sofia, 1797, Bulgaria
    Recruiting
  • Climb Bio Investigative Site #300204
    Athens, Attica 11527, Greece
    Recruiting
  • Climb Bio Investigative Site #300203
    Chaïdári, Attica 12462, Greece
    Recruiting
  • Climb Bio Investigative Site #300202
    Ioannina, 45500, Greece
    Recruiting
  • Climb Bio Investigative Site #300201
    Thessaloniki, 57010, Greece
    Recruiting
  • Climb Bio Investigative Site #381201
    Belgrade, Serbia
    Recruiting
  • Climb Bio Investigative Site #381202
    Belgrade, Serbia
    Recruiting
  • Climb Bio Investigative Site #381203
    Novi Sad, Serbia
    Recruiting
  • Climb Bio Investigative Site #340206
    Burgos, 9006, Spain
    Not yet recruiting
  • Climb Bio Investigative Site #340204
    Madrid, 28041, Spain
    Recruiting
  • Climb Bio Investigative Site #340202
    San Pedro, Spain
    Recruiting
  • Climb Bio Investigative Site #340203
    Valencia, 46010, Spain
    Recruiting
  • Climb Bio Investigative Site #380208
    Cherkasy, Ukraine
    Not yet recruiting
  • Climb Investigative Site #380204
    Ivano-Frankivsk, Ukraine
    Recruiting
  • Climb Investigative Site #2380203
    Kyiv, Ukraine
    Recruiting
  • Climb Investigative Site #380202
    Kyiv, Ukraine
    Recruiting
  • Climb Investigative Site #380206
    Kyiv, Ukraine
    Recruiting
  • Climb Investigative Site #380201
    Lviv, Ukraine
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07043946
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jun 30, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Climb Bio Study Director
Contact
clinicaltrials@climbbio.com
+1 866 857 2596
Study Director
study director · Climb Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion